Orphan Drugs in MENA

In Market Access, Whitepapers by Freya SmaleLeave a Comment

Global Overview of Orphan Drug Market

Disease that have low prevalence rates are no less important than ones that have a higher incidence. Few of the countries have laws to determine the treatment and approach to orphan disease, and there are criteria that establish whether or not a disease can be classified in the first place. In Japan, a disease that affects less than 50,000 persons is an orphan disease. In US, this number is 200,000.1

Orphan drugs is a niche buster because they provide an ideal venue for companies to offset the lapsing patents and shrinking pipelines of blockbuster drugs. In such cases orphan drugs bring forth a new business model.1

The total number of disease categorized as orphan are stands at about 7,000 currently, with nearly 250 new disease being appended to this list annually. 1

Download the whitepaper as provided by Mesned now to find out more about:

  • Global Overview of Orphan Drug Market
  • Healthcare in KSA
  • Prevalence of Orphan Disease in MENA
  • Orphan Drug Market in KSA
  • Clinical Trial Opportunities

Get your copy here >

  1. Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 – 2018.

MPCC is joining us the World Orphan Drug Congress USA 2015. It’s not too late to join them – simply click the banner below to book.


Leave a Comment